Monopar Therapeutics Inc.

Monopar Therapeutics Inc.

MNPR · Nasdaq

Monopar Therapeutics Inc. (MNPR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Monopar Therapeutics Inc. in 2026. The next earnings report is expected on November 6, 2026.

Earnings calendar

Next earnings date

06 Nov 2026

In 78 days

EPS estimate

-0.80

Revenue estimate

0

Past earnings

12 Aug 2026
EPS actual
-0.62 (+3.5%)
estimate -0.64
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 May 2026
EPS actual
-0.46 (+31.7%)
estimate -0.67
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
27 Mar 2026
EPS actual
-0.59 (-22.6%)
estimate -0.48
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 Nov 2025
EPS actual
-0.48 (-24.1%)
estimate -0.39
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Monopar Therapeutics Inc. beat consensus on EPS, reporting a loss per share of $0.62 versus an estimated loss of $0.6425, and revenue matched expectations at $0. In the prior quarter EPS also came in ahead of expectations while revenue again met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Chandler D. Robinson
Employees
14
IPO date
19 Dec 2019
ISIN
US61023L2079
Website
monopartx.com

Frequently asked questions

When does Monopar Therapeutics Inc. (MNPR) next report earnings?

Monopar Therapeutics Inc. (MNPR) is scheduled to report earnings on November 6, 2026.

What was Monopar Therapeutics Inc.'s most recent earnings date?

Monopar Therapeutics Inc. (MNPR) last reported earnings on August 12, 2026.

Where is Monopar Therapeutics Inc. stock listed?

Monopar Therapeutics Inc. (MNPR) is listed on Nasdaq.